Scilex (SCLX) Stock Price, News & Analysis

Company Overview

Scilex Holding Company is a commercial-stage pharmaceutical company focused on developing and commercializing non-opioid treatments for acute and chronic pain. The company’s portfolio includes prescription products intended to address conditions such as neuropathic pain, migraine and gout-related pain and inflammation.

Scilex markets ZTlido, a prescription topical lidocaine system approved for the relief of pain associated with postherpetic neuralgia. Its portfolio also includes ELYXYB, an oral solution of celecoxib approved for the acute treatment of migraine with or without aura in adults, and GLOPERBA, an oral liquid colchicine product indicated for the treatment and prevention of gout flares in adults.

The company has also pursued additional investigational pain therapies, including product candidates designed for localized and non-opioid pain relief. Scilex primarily serves the United States through prescription pharmaceutical channels and commercial partnerships. Jaisim Shah has served as the company’s chief executive officer and president. Scilex was established as a specialty pharmaceutical business and became a publicly traded company through a business combination in 2022.

Key Stats

• Today's Range: $4.42 to $4.54
• 50-Day Range: $4.49 to $7.84
• 52-Week Range: $4.20 to $27.00
• Volume: 1,593 shs
• Average Volume: 79,602 shs
• Market Capitalization: $37.71 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Scilex Stock Analysis - MarketRank™

Scilex scored higher than 4% of companies evaluated by MarketBeat, and ranked 877th out of 900 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Scilex has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Scilex has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Scilex is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Scilex is -0.09, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.18% of the float of Scilex has been sold short.

Short Interest Ratio / Days to Cover

Scilex has a short interest ratio ("days to cover") of 5.89.

Change versus previous month

Short interest in Scilex has recently increased by 11.19%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Scilex does not currently pay a dividend.

Dividend Growth

Scilex does not have a long track record of dividend growth.

News and Social Media

• Score: 2.2 / 5
• News Sentiment: 0.55

News Sentiment

Scilex has a news sentiment score of 0.55. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.75 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Scilex this week, compared to 2 articles on an average week.

Search Interest

Only 1 people have searched for SCLX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

2 people have added Scilex to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Scilex insiders have not sold or bought any company stock.

Percentage Held by Insiders

4.50% of the stock of Scilex is held by insiders.

Percentage Held by Institutions

69.67% of the stock of Scilex is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/29/2026
• Next Earnings (Estimated): 12/02/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:SCLX
• CIK: 1820190
• Web: www.scilexholding.com
• Phone: 650-516-4310
• Fax: N/A
• Employees: 34
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($49.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$358.73 million
• Net Margins: -1,414.57%
• Pretax Margin: -1,469.71%
• Return on Equity: N/A
• Return on Assets: -147.00%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.07
• Quick Ratio: 0.06

Sales & Book Value

• Annual Sales: $30.25 million
• Price / Sales: 1.27
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($24.94) per share
• Price / Book: -0.18

Miscellaneous

• Outstanding Shares: 8,490,000
• Free Float: 8,111,000
• Market Cap: $38.49 million
• Optionable: No Data
• Beta: 1.65